Merck Reports FDA Approved KEYTRUDA As Monotherapy for Patients with Metastatic Small Cell Lung Cancer (SCLC) with Disease Progression on or After Platinum-Based Chemotherapy and at Least One Other Prior Line of Therapy
Benzinga Newsdesk